Cedars-sinai Medical Center

Black Light Surgical, Inc.

Other

Yeda Research and Develpment & Co. Ltd

Arrogene Nanotechnology, Inc.

University of California

Arrogene, Inc.

Keith L Black

Julia Y Ljubimova

Eggehard Holler

John S Yu

Gentao Liu

Maya Koronyo

Yosef Koronyo

Rameshwar Patil

Hui Ding

Jack Kavanaugh

Pramod Butte

Bartosz Bortnik

Zhaojun Nie

Anthony B Nesburn

Christopher J Wheeler

Daniel L Farkas

Moshe Arditi

Steven L Wechsler

Michal Schwartz

Alexander Ljubimov

Dwain Morris-Irvin

Altanchimeg Rentsendorj

Satoshi Inoue

Nagendra S Ningaraj

Guey-Chuen Perng

Asha Das

Haoshen Shi

The present invention describes a method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. The method involves the detection of pericyte loss and deficiency in PDGFRβ, alone or in combination with retinal vascular Aβ deposits. The method also involves detecting an alteration in blood-retinal barrier (BRB) cell tight junction.

Method of detecting cognitive impairment

Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.

Systems, devices, and methods for time-resolved fluorescent spectroscopy

The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.

Methods of treating or preventing alzheimer's disease and associated conditions

Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other 'non-typical' peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.

Visual stimuli maze test for detecting visual abnormalities in prodromal Alzheimer's disease and in Alzheimer's disease

Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (&#x3b2;-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

Polymalic acid-based nanobiopolymer compositions

The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A&#x3b2;-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

Optical method for the detection of Alzheimer's disease using curcumin

Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.

Polymalic acid based nanoconjugates for imaging

Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

Cancer vaccines and vaccination methods

Optical method for detecting Alzheimer's disease by systemic administration of curcumin

The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.

Drug delivery of temozolomide for systemic based treatment of cancer

Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.

Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors

Growing community of inventors

Los Angeles, CA, United States of America

Keith L Black